Introduction
First proposed by Nowell (1976) , it is now widely accepted that tumors arise from single cells that have acquired abnormal proliferative capability. This is a multistep progression during which the activity of cellular growth-promoting genes, termed oncogenes, is increased and the activity of genes that normally serve to constrain growth, termed tumor suppressors, is lost or diminished (Fearon and Vogelstein, 1990; Kinzler and Vogelstein, 1996) . Consequently, such relaxation of cellular controls over both positive and negative regulators of growth may act to propel the cell toward an increasingly malignant form of growth. Knudson (1971) hypothesized that loss of tumor suppressor activity occurs via a`two-hit' mechanism. Speci®cally, an individual possessing one functional allele of a tumor-suppressor molecule must undergo a single mutational event, while an individual possessing two functional copies of the allele must undergo two distinct mutational events to lose function of the given gene.
A prominent mechanism for loss of gene function is through deleterious changes (mutations) to the genome. Such events can stem from simple changes in the genome (i.e., point mutations or small insertions/ deletions), or can be more complex such as gross chromosomal rearrangements (i.e., inversions, translocations). Often, such events result in the functional inactivation of one or more genes. For example, the human autosomal recessive disorder Ataxia-Telangiectasia (A-T) is caused by function ablating mutations within the ATM gene (Savitsky et al., 1995) . The ATM gene product is a high-molecular weight protein kinase proposed to play a pivotal role in triggering appropriate cellular response to genome damage (Brown et al., 1999; Rotman and Shiloh, 1998) . Loss of ATM function is responsible for the high rate of chromosomal aberrations observed in A-T cells and the increased frequency of somatic cell mutations in individuals with A-T (Bigbee et al., 1989; Pandita and Hittelman, 1994 ). An unsurprising outcome of the compromised genomic integrity displayed by ATM-de®cient cells is the development of cancer. Indeed, A-T patients possess a 70-fold higher incidence rate of leukemia and a 250-fold elevated incidence rate of lymphoma compared to normal individuals (Morrell et al., 1986) . Additionally, Atm-de®cient mice invariably develop and succumb to aggressive thymic lymphoma (Barlow et al., 1996) . Besides the inheritance of homozygous ATM mutations through the germline, loss of ATM function through somatic gene mutation has been observed in several forms of leukemia (Xu, 1999) . These observations have led to the view that ATM functions as a tumor suppressor in cells of lymphocytic origin and, perhaps, in other tissue types as well (Khanna, 2000) .
While gene mutation is clearly one mechanism that can lead to loss of tumor suppressor function, another mechanism that has received much attention as of late is the methylation of cytosine residues within the genome, speci®cally cytosines located within the 5'-CG-3' dinucleotide. Through evolution, CpG dinucleotides have become depleted in the genome and most are now located within small (500 ± 2000 bp) stretches of the genome referred to as CpG islands. CpG islands are commonly located within or in close proximity to the transcriptional start sites of many genes, and CpG methylation generally results in the transcriptional repression of nearby gene(s) (Bird, 1992) . Such methylation events are responsible for the silencing of several genes known to encode proteins important in limiting tumor development and/or progression such as p16
INK 4a (Costello et al., 1996) , E-cadherin (Hiraguri et al., 1998) , the Von Hippel-Lindau (VHL) gene product (Herman et al., 1994) , the BRCA1 breast cancer tumor suppressor protein (Esteller et al., 2000) , and the mismatch repair (MMR) protein hMLH1 (Kane et al., 1997; Veigl et al., 1998) . While this represents a modest list of targeted proteins, it seems inevitable that, given the intense level of interest in this area, more genes will be recognized as targets for methylation-induced gene silencing during cancer development.
Results
The colorectal tumor cell line HCT-116 displays moderate radiosensitivity and reduced ATM expression ATM plays a key role in triggering responses to the genotoxic eects of ionizing radiation (IR) by phosphorylating/activating a cadre of downstream targets such as p53, c-abl, p95/NBS1, and chk2 (Brown et al., 1999; Kastan and Lim, 2000) . Recent ®ndings indicate that DNA alkylating agents trigger MMR system-dependent p53 phosphorylation in a manner that resembles IR-induced response (Duckett et al., 1999; Hickman and Samson, 1999) . To determine if loss of MMR proteins leads to increased sensitivity to IR, we conducted clonogenic survival assays on a panel of three MMR-defective HNPCC cell lines, ATMde®cient, and normal human ®broblasts ( Figure 1a ). As expected, an A-T line (GM5849C) exhibited extreme radiosensitivity. The radiosensitivity of the MSH-2 de®cient LoVo cell line overlapped that of normal human diploid ®broblasts (NHF), RKO cells (MLH1-de®cient) were slightly more radioresistant than NHF, and HCT-116 (MLH1-de®cient) cells displayed moderate radiosensitivity compared to NHF (MMR protein de®ciency in each HNPCC line was con®rmed by immunoblotting ± data not shown.)
Close inspection of the radiosensitivity of HNPCC cells (Figure 1b ) failed to show that the increased radioresistance by RKO, compared to LoVo cells was signi®cant (P=0.365 at 10 Gy). However, HCT-116 cells were found to have heightened radiosensitivity compared to both LoVo and RKO. For example, following 10 Gy of IR we measured a mean survival of 3.5% (+0.15% s.d., n=6) in LoVo and 4.3% (+0.25% s.d., n=4) in RKO. At the same dose we measured 1.2% (+0.2% s.d., n=4) survival in HCT-116 cells. Using the Student's t-test (two-tailed) we determined that the dierence in the radiosensitivity displayed by HCT-116 and LoVo at 10 Gy is signi®cant (P=0.008).
The radiosensitive phenotype of A-T cells is directly attributable to loss of ATM expression (Ziv et al., 1997) and heterozygotes display a moderate level of radiosensitivity, presumably owing to reduced levels of ATM (Chen et al., 1978) . We observed that NHF, LoVo, and RKO cells express detectable levels of the *350 kD ATM protein when 50 mg of total cell lysate was probed with the anti-ATM monoclonal antibody AM-9 at 1 : 10 dilution ( Figure 1c , top panel). However, we failed to detect ATM in lysates from HCT-116 cells under these immunoblotting conditions. Immunoblotting with tubulin antibody con®rmed equivalent protein loading ( Figure 1c , bottom panel). When a greater load of total cell lysate (100 mg) from LoVo and HCT-116 cells was probed with a lower dilution (1 : 4) of AM-9, we detected ATM in HCT-116 extract ( Figure 1d ). Densitometric analysis determined that HCT-116 cells express 4.7-fold (n=4, +0.6 s.d.) less ATM than LoVo cells.
Treatment of HCT-116 cells with 5-azacytidine results in transient upregulation of ATM abundance
To explain the dramatically reduced level of ATM in our HCT-166 cells, we hypothesized that expression of the ATM gene was silenced via aberrant promoter methylation because the proximal promoter of the ATM gene is located within a CpG island (Byrd et al., 1996; Imai et al., 1996) . To test this, we exposed cultures of HCT-116 cells to two sequential doses of the global demethylating agent 5-azacytidine as previously outlined (Veigl et al., 1998) . Brie¯y, 5-azacytidine was added to the culture media of asynchronous cultures to a ®nal concentration of 5 mM. Following a 24 h incubation with drug, the cells were rinsed with PBS, fresh culture media was added and the cells returned to the incubator for 24 h. At the end of this incubation, 5-azacytidine (5 mM) was again added and the cells incubated with drug for another 24 h. Following this ®nal treatment, the cells were washed with PBS, fresh media added and subcultured when cells reached con¯uency. Extracts were formed at indicated time points where day one (d1) is the initial day of 5-azacytidine treatment.
A low level of ATM was detected in untreated HCT-116 cells, but in cells harvested on day 6 (d6) of the treatment protocol a 6.4-fold increase (+1.1 s.d., n=5) in ATM abundance was observed ( Figure 2a , top panel). Further, this rise in ATM abundance was sustained through d20. Tubulin levels were also assayed, and no change in the levels of this protein was observed ( Figure 2a , middle panel). Equal protein loading was con®rmed by Coomassieblue staining a gel run in parallel (Figure 2a, bottom panel) . In an independent experiment, we also harvested treated cells on d30 (Figure 2b) . A sharp increase in ATM levels at d6 ± d20 was observed, but by d30, ATM abundance dropped to a level comparable to untreated cells. No¯uctuation in ATM abundance was observed in NHF in response to 5-azacytidine treatment (Figure 2c ), indicating that 5-azacytidine treatment did not exert an eect on ATM abundance in this cell type.
The proximal promoter region of the ATM gene is aberrantly methylated in HCT-116 cells
The putative proximal promoter of the ATM gene is a *520 bp region shared with the NPAT/E14/CAND3 gene (Byrd et al., 1996; Imai et al., 1996; Chen et al., 1997) . Owing to the placement of this region between two genes transcribed in opposite orientation, and supported by reporter assays, it has been proposed that this sequence is a bi-directional promoter (Byrd et al., 1996) . We have cloned and sequenced this region from HCT-116 genomic DNA and found it to contain no mutations (data not shown).
We examined methylation of the ATM promoter region in HCT-116 cells at the two HpaII/MspI sites (5'-CCGG-3') located within this intergenic region (Figure 3a) . Speci®cally, methylation was detected by the ability to amplify a segment of the ATM promoter by PCR after digestion of genomic DNA with HpaII (will not digest methylated palindrome) or MspI (digestion is insensitive to methylation status of the palindrome) (Kane et al., 1997) . We observed that the test-1 PCR product could be ampli®ed from both undigested and HpaII digested, but not MspI digested HCT-116 DNA (Figure 3b, top panel) . Similar results were obtained with the test-2 PCR reaction ( Figure 3b , middle panel). We were unable to amplify either of the test fragments form HpaII and MspI digested DNA isolated from HCT-116 cells treated with 5-azacytidine ( Figure 3c ). Likewise, analysis of NHF genomic DNA was concordant with a lack of ATM promoter methylation in these cells (Figures 3d) . Consistent ampli®cation of a fragment of the ATM promoter that does not overlap the HpaII/MspI sites con®rmed the integrity of the DNA used in these analyses ( Figure  3b ± d, bottom panels). These results are consistent with HCT-116 cells containing aberrantly methylated CpG dinucleotides within the ATM proximal promoter region. We have conducted similar analysis on genomic DNA harvested from LoVo and RKO cells and found no evidence for ATM promoter methylation in these cells (data not shown).
NPAT expression and localization are unaffected in HCT-116 cells
NPAT is a *220 kD protein that interacts with the Cyclin E/Cdk2 complex and accelerates S phase entry when overexpressed in cultured cells (Zhao et al., 1998) . As outlined above, it has been proposed that the *520 bp intergenic region located between the NPAT and ATM genes functions as a bi-directional promoter (Byrd et al., 1996) . Since aberrant methylation of this region leads to a marked reduction in ATM abundance, it is reasonable that a similar eect may occur with respect to NPAT expression.
To test this notion, we immunoblotted extracts from LoVo and HCT-116 cells with an anti-NPAT antiserum. The results showed no discernable dierence in NPAT abundance in the two cell lines (Figure 4a We also used the anti-NPAT antiserum to localize this protein in LoVo and HCT-116 cells by immuno-¯u orescence microscopy. We observed staining of a limited number of discreet foci in both LoVo and HCT-116 cells (Figure 4b,c, respectively) . Further, counterstaining with Hoescht 33286 con®rmed the nuclear localization of these foci (Figure 4d,e) . This staining pattern is consistent with a previous report that documented co-localization of NPAT with Cajal Following thermocycling, equivalent volumes of each reaction were subjected to electrophoresis followed by ethidium bromide staining (coiled) bodies, intranuclear organelles associated with histone gene clusters (Ma et al., 2000) . Taken together, our ®ndings indicate that aberrant methylation of the NPAT/ATM intergenic region does not adversely eect either NPAT expression of localization.
Treatment of HCT-116 cells with 5-azacytidine restores normal radiosensitivity
We reasoned that reduced ATM expression attributable to promoter methylation may be responsible for the heightened radiosensitivity displayed by HCT-116 cells. To test this, we took advantage of the observation that 5-azacytidine treatment raised the ATM level in HCT-116 to an abundance equivalent with that present in NHF (see Figure 2a) . HCT-116 cells were 5-azacytidine treated and subsequently assayed for clonogenic survival following IR. The results of this experiment ( Figure 5 ) indicated that 5-azacytidine treated HCT-116 cells possessed a radiosensitivity pro®le that overlaps that of NHF. These ®ndings clearly imply that the moderate radiosensitivity displayed by HCT-116 cells can be reversed by 5-azacytidine treatment, and that this correlates with increased ATM abundance.
Discussion
We addressed our initial idea that loss of MMR would result in a diminished ability to appropriately respond to IR by quantifying radiosensitivity in a panel of three MMR-de®cient colorectal tumor lines. Two of these lines displayed levels of radiosensitivity consistent with that displayed by normal human ®broblasts, while the other line, HCT-116, showed moderate radiosensitivity. Furthermore, this moderate radiosensitivity was corrected by treatment with the demethylating agent 5-azacytidine, and this outcome correlates with a dramatic upregulation of the ATM protein in these cells. Given these observations, we conclude that loss of MMR has no adverse eects on the cell's ability to respond to the cytotoxic eects of ionizing radiation. A similar conclusion was reached by Yan and coworkers in studies that used isogenic MMR-pro®cient and -de®cient human lines (Yan et al., 2001) . Moreover, analysis of radiosensitivity in mouse cell lines with engineered defects in several dierent MMR proteins showed that these cells were slightly more radio- resistant than matched control lines (Fritzell et al., 1997) . Thus, it is clear that loss of MMR does not negatively in¯uence cellular response to the cytotoxic eects of IR exposure as judged by clonal survival.
Our ®ndings are consistent with aberrant methylation of the ATM proximal promoter being responsible for the quantitatively reduced levels of ATM present in HCT-116 cells. This interpretation is based in experiments that employ both indirect biochemical (immunoblotting of 5-azacytidine treated cells) and direct molecular biological (PCR analysis of genomic DNA) approaches to examine promoter methylation. While methylation of the two 5'-CCGG-3' palindromes located within the proximal ATM promoter investigated in our study does occur, and its demethylation is clearly linked to increased ATM expression, it is currently unclear as to which methyl-CpG dinucleotides within the proximal promoter region are critical for silencing ATM expression. Considering that there are extensive CpG dinucleotides within the 520 bp proximal promoter region of the ATM gene, the methylation pattern of this segment of the genome is potentially complex.
Aberrant methylation of CpG islands is a frequently encountered feature in colorectal tumor line Kane et al., 1997; Lengauer et al., 1997; Toyota et al., 1999; Veigl et al., 1998) . Given this, and the observation that we (data not shown) and others (Ejima et al., 2000) , have found variable levels of ATM expression in several dierent strains of HCT-116 cells (the strain of HCT-116 used in this study was obtained directly from ATCC), we cannot conclude that the ATM gene is commonly targeted for silencing in HCT-116 cells. We have also documented normal levels of ATM expression in the colorectal tumor lines LoVo and RKO (see Figure 1c) , and two additional HNPCC lines HCT-15 and SW-48 (data not shown). Thus, the bulk of evidence suggests that epigenetic silencing of ATM expression is not a prevalent event in colorectal tumor lines. Clearly, study of additional HNPCC cell lines and tumor cells in situ is required to assess a potential link between silencing of the ATM gene and hereditary and/or sporadic colorectal cancers.
While ATM expression is suppressed in the HCT-116 line used in this study, these cells showed no diminishment in NPAT expression when compared to LoVo cells. The ATM and NPAT genes share a common *520 bp intergenic region located on human chromosome 11, region q22-23 (Byrd et al., 1996; Imai et al., 1996) . Based on the location of this segment between the two genes that run in opposite orientation, and supported by reporter assays that show that both orientations of this region promote transcription in vivo, it has been proposed that this intergenic interval is a bi-directional promoter (Byrd et al., 1996) . Our ®nding that aberrant methylation can drastically in¯uence ATM expression while exerting no eect on NPAT abundance suggests that expression of these two genes are controlled, at least in part, by non-overlapping regions of the genome.
Studies of gene hypermethylation in a variety of tumors indicate that such epigenetic changes often give rise to a tumor spectrum that mimics the tumor pattern observed with mutational disruption to the same gene Herman and Baylin, 2000) . For example, mutational inactivation and hypermethylation of the von Hippel-Lindau (VHL) gene appear to be causal events for the majority of spontaneous clear-cell real carcinomas (Herman et al., 1994; Gnarra, 1998) . If such a relationship also holds true for the ATM gene, then the development of leukemias and/or lymphomas are likely candidate tumors linked to epigenetic silencing of ATM expression due to the high incidence of leukemia/lymphoma observed in humans and mice harboring inactivating mutations with ATM (Barlow et al., 1996; Taylor et al., 1996) .
Another potential candidate tumor for epigenetic silencing of ATM expression is breast cancer, since ATM heterozygotes are at risk for an elevated rate of breast tumors (Athma et al., 1996; Swift et al., 1987) . Numerous studies have failed to detect elevated rates of truncating ATM mutations in breast cancer patients (for review see Gatti et al., 1999) . While more recent studies have found that an increased incidence of missense ATM mutations in breast cancer cohorts (Dork et al., 2001; Teraoka et al., 2001) , the link between diminished ATM function and breast cancer remains elusive. Aberrant methylation of the ATM proximal promoter, and consequential silencing of ATM expression, is an attractive candidate mechanism to explicate this conundrum.
In conclusion, we have demonstrated that the ATM gene is a target for silencing through aberrant methylation of its proximal promoter region. This epigenetic event can result in decreased expression of ATM, resulting in a cellular phenotype consistent with reduced ATM function. Given that ATM plays a pivotal role in activating cell cycle checkpoints after DNA damage, and that loss of ATM results in gross genomic instability, this protein is a potential target for functional inactivation during the process of tumorigenesis. The ®nding that promoter hypermethylation can result in diminishment of ATM function raises the formal possibility that this mechanism of ATM inactivation plays a role in the process of cancer development.
Materials and methods

Cell culture
Normal diploid foreskin ®broblasts (NHF) were established from foreskins taken from infants circumcised at LSU University Hospital and were subsequently grown in DMEM supplemented with 10% fetal calf serum (FCS). The SV-40 transformed A-T ®broblast line GM05849C was obtained from the NIGMS Human Genetic Mutant Cell Repository (Camden, NJ, USA) and cultured as outlined. The HNPCC cell lines HCT-116 and LoVo were obtained from the American Type Tissue Collection (Manassas, VA, USA) and cultured as instructed. RKO cells were a gift from Dr Tej Pandita (Columbia University) and were cultured in DMEM supplemented with 10% fetal calf serum. All lines were cultured at 378C in a humidi®ed 5% CO 2 atmosphere.
Radiosensitivity analysis
Radiosensitivity was assessed using the method outlined by Ziv et al. (1997) . Cells were harvested by trypsinization and replated at known density in tissue culture¯asks and then returned to the incubator for 18 ± 24 h. Cells were exposed to the indicated dose of ionizing radiation from a 137 Cs source (Gammacell 1000, Atomic Energy of Canada Ltd; dose rate=318 rad/min) and following irradiation were returned to the incubator. Non-irradiated cells were cultured in parallel to determine relative plating eciency of each line. Ten days post-irradiation, the media was removed, cells were stained with crystal violet and colonies consisting of 550 cells were scored. Three to six individual survival values (per cent survival) for each IR dose were plotted.
5-Azacytidine treatment
Treatment of cells with 5-aza-2'-deoxycytidine (5-azacytidine) was conducted as previously outlined (Veigl et al., 1998) . Brie¯y, asynchronous cultures of cells were grown to approximately 70% con¯uency in complete growth media and 5-azacytidine (Sigma) was added to the culture media to a ®nal concentration of 5 mM. Following a 24 h incubation with drug, the cells were rinsed with PBS, fresh culture media was added, and the cells returned to the incubator for 24 h. At the end of this incubation, 5-azacytidine (5 mM) was again added, and then cells incubated with drug for another 24 h. Following this ®nal treatment, the cells were washed with PBS, fresh media added, and subcultured when cells reached con¯uency. Extracts were formed from the cells at indicated timepoints where day one (d1) is the initial day of 5-azacytidine treatment.
SDS ± PAGE and immunoblotting
SDS ± PAGE, electrotransfer of the gels to nitrocellulose sheets, and antibody labeling was conducted as outlined . Immunoreactive bands were visualized using Supersignal CR-HRP (Pierce) chemiluminescent substrate and recorded on Kodak XAR X-ray ®lm. Quantitation of immunoblot signals was performed using an Agfa SnapScan¯atbed scanner and the NIH Image (version 1.62) software package. ATM was detected using the mouse monoclonal antibody AM-9 (Barlow et al., 2000) , tubulin with the monoclonal antibody DM1A, and NPAT with a polyclonal antisera raised in rabbits (obtained from Dr Wade Harper, Baylor College of Medicine).
Prior to electrophoresis, protein concentrations were determined using a BCA assay (Pierce). Equivalent protein loadings were con®rmed by subjecting 35 mg of total cell extract to SDS ± PAGE on 10% acrylamide gels followed by Coomassie-blue staining.
Analysis of ATM promoter methylation
Genomic DNA was isolated from indicated cell lines using a Wizard Genomic DNA Puri®cation Kit (Promega). Prior to thermocycling with indicated primer sets, 15 mg of genomic DNA was digested with 30 U of HpaII or MspI for 18 h at 378C, subsequently phenol/chloroform extracted, ethanol precipitated, and resuspended in H 2 O. One hundred ng of DNA was added to a 50 ml PCR reaction containing 16 PCR buer/0.8 mM dNTP/1.5 mM MgCl 2 /150 ng of forward primer/ 150 ng of reverse primer/2.5 U AmpliTaq Polymerase (Perkin Elmer). Thermocycling was conducted using the following protocol: Initial cycle, 958C for 5 min; subsequent cycles (406), 958C for 30 s, 508C for 45 s, 728C for 45 s. Following completion of thermocycling, an aliquot of the PCR reaction was subjected to electrophoresis on a 10% non-denaturing acrylamide gel and stained with ethidium bromide. The identity of the 326 bp test-1 fragment, 399 bp test-2 fragment, and 210 bp control fragment was veri®ed by sequencing.
Oligonucleotide primers
The deposited sequence of the ATM proximal promoter region (GenBank accession # D83244) was used to design PCR primers. The primers used for PCR were: Test-1 fragment: sense: 5'-ctgtcgtcacttccgtcc-3'; antisense: 5'-cctactcccgcttccggttc-3'.
Test-2 fragment: sense: 5'-gaatgttttggggcagtgtt-3'; antisense: 5'-tgaggagagggaggagtcaa-3'. Control fragment: sense: 5'-ccacagcaggaaccacaa-3'; antisense: 5'-ggacggaagtgacgacag-3'. Primers were obtained from Integrated DNA Technologies (Coralville, IA, USA).
Immunofluorescence microscopy
Indirect immuno¯uorescence microscopy was conducted as previously outlined (Brown et al., 1994) . LoVo and HCT-116 cells were cultured on sterilized glass coverslips. The cells were ®xed by immersion in PBS containing 3.0% formaldehyde for 30 min at RT, after which the cells were permeabilized by immersion in PBS containing 0.1% Triton X-100. Following this step, the coverslips were rinsed in PBS and blocked by immersion in PBS containing 5% bovine serum albumin (BSA). Immuno¯uorescence staining was done using rabbit anti-NPAT followed by FITC-labeled anti-rabbit secondary antibody (Kirkegaard and Perry Labs, Gaithersburg, MD, USA). Cells were counterstained with Hoescht 33258 (0.1 mg/ml ®nal conc.) to reveal DNA. Images were captured on a Leitz microscope equipped with a SPOT CCD camera.
